Menu

Rapid Adoption of Carterra’s LSA™ Instrument Drives European Expansion

Carterra® Inc., the world leader in high-throughput antibody screening and characterization, announced today that they have opened a Customer Experience Center (CEC) and office in Munich, Germany.

Aug 15, 2019
Carterra, Inc.

Carterra® Opens a Customer Experience Center in Munich

Rapid European adoption of Carterra’s platform has fueled the need for the new office.

 The Munich CEC will be a place for researchers throughout Europe to gain first-hand experience with Carterra’s game-changing antibody screening platform, the LSA, through demonstrations and workshops.  Carterra will also offer basic courses in label-free biosensor operation, experimental design, and data analysis.  Since its launch in 2018, the LSA is installed on three continents and in a majority of the largest pharmaceutical companies in the world.  To support this exponential worldwide growth, Carterra has hired direct sales, support, and service personnel in Europe, most of whom are based in the Munich office.

 Traditional antibody discovery requires a primary screen of ever-expanding antibody libraries by low-resolution “yes/no” assays to identify binders.  Only a small group of candidate antibodies are then characterized on traditional, low-throughput biosensor tools, which provide real-time readout of the full binding profile.  This workflow runs the risk that potential blockbuster drug candidates could be missed.

 Carterra’s LSA is turning that model on its head by enabling the high-resolution analysis of entire libraries, combining screening and characterization into one seamless step, thereby minimizing the risk of missing a blockbuster.  The LSA’s dramatic throughput condenses months of work into days.

 Additionally, the LSA offers investigators the most resolved view of the epitope – the location an antibody binds to its target.  An epitope is an innate property that cannot be changed and must be discovered empirically.  The LSA is the only technology that enables characterization of epitope binding at the full library level.  This provides biologics developers an enormous advantage in differentiating their biomolecules from competitors’ drugs and in establishing intellectual property claims.

 “The LSA is changing the way biologics are discovered,” says Tim Germann, Carterra’s Chief Commercial Officer.  “We’re thrilled to invite European drug developers and the research community at large to experience in person the massive throughput and minuscule sample requirements that the LSA enables.  We’re making the traditional discovery processes up to 100 times faster while using only 1% of the normal sample input-it’s the definition of disruptive.” 

September 2019

Our Inner Neanderthal

Ancient secrets in the human genome

Marketplace

Sponsored Product Updates

Evaluating the Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin
Evaluating the Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin
Download this application note to learn how the ACEA xCELLigence system can evaluate the potency of an immunotherapy against a broad spectrum of liquid tumors and monitor the destruction kinetics of liquid cancers at physiologically relevant effector:target cell ratios.
Kinetics of Tumor Cell Killing by Tumor-Infiltrating Leukocytes
Kinetics of Tumor Cell Killing by Tumor-Infiltrating Leukocytes
Watch this webinar to learn how Dr. Cara Haymaker and her team are assessing the reactivity of tumor-infiltrating lymphocytes and modulating the mechanisms of resistance to therapy and exploring biomarkers involved in the response.
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
Atlas Antibodies AB, a leading supplier of advanced research reagents, announced today the introduction of pre-quantified QPrEST™ Protein Standards for absolute quantification of proteins in biological samples such as cell lysate and plasma using liquid chromatography (LC)–mass spectrometry (MS).
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
CORNERSTONE program integrates process development expertise and novel technology to remove development bottlenecks in the manufacture of Gene Therapy Medicinal Products (GTMPs). Portfolio includes novel CIMasphere™ technology for higher yielding processes and safer products in AAV-based programs